On its way out the door, the Biden Administration just released new guidelines for those seeking to license inventions made at the National Institutes of Health (NIH) that could lead to new “drugs, biologics (including vaccines) or devices for the prevention, diagnosis or treatment of human disease.” The administration has claimed this is being done “to expand patient access to products that emerge from NIH-owned inventions.” The guidelines apply to all licenses, exclusive and non-exclusive.
Recent Posts
- Fox Succeeds in Scrapping Machine Learning Claims at CAFC Under 101
- Other Barks & Bites for Friday, April 18: CAFC Affirms Ineligibility of Machine Learning Claims; EPO’s Campinos Issues Opinion on Intervener Appeals; USPTO Ends Climate Change Mitigation Program
- In Latest Antitrust Blow for Google, Judge Finds Search Giant Monopolizes Certain Ad Tech Markets
- New USPTO Group to Crack Down on Threats to U.S. Patent System
- IP, Globalization and the Future of Supply Chains: A Conversation with Sonja London | IPWatchdog Unleashed